Oxeltis

Executive Summary

Oxeltis is a privately held French medicinal chemistry service company based in Montpellier, specializing in providing competencies and resources for medicinal and fine organic chemistry projects. Founded in 2007, the company supports pharmaceutical, diagnostic, and academic research organizations with expertise in drug discovery and development. With a focus on custom synthesis, lead optimization, and scale-up chemistry, Oxeltis positions itself as a reliable partner for outsourced R&D needs. The company operates in the regenerative medicine and medical devices sectors, leveraging its chemical synthesis capabilities to serve clients globally. Despite being a service provider rather than a product-focused biotech, Oxeltis plays a critical role in the drug development value chain by enabling preclinical and clinical-stage programs. The company's private status and lack of disclosed financials make it difficult to assess its market position, but its long-standing presence in the European CRO landscape suggests steady operations and client loyalty.

Upcoming Catalysts (preview)

• Q4 2026Major Partnership or Multi-Year Contract with a Top Pharma40% success
• Q2 2027Expansion of Laboratory and Manufacturing Capacity60% success
• Q3 2027Regulatory Approval for a Client's Drug Candidate Using Oxeltis Chemistry30% success